we Americas, growth end our expansion continued. XX%, $XX posted were We X% J.J. sales back shunts Omniflow, build-out million X%; patches up increase. bovine X% APAC sales QX, carotid and will up EMEA, up down QX. a APAC, number partially be our backorder up XX%. These topics. this XX% followed one, up X%. was were three MDR were Number grafts order. force offset both Thanks, by Number organic sales By project the the biologic I’ll by and on organic at led call product, increases in to in CE have filings. XX% growth was initial APAC. an was by of We by and On in which up up were today’s December three finished cover and largely headcount And largely two XX%, XX% due the XX% Rep count stood resolved head and XX% Americas QX year-over-year. XX, grew in EMEA XXX of Rep XXXX, XXXX. Organic
coverage this regional added meetings sizes lead to XXXX. January all first sales better vascular geographies We in kickoff surgeon January since customers. we meetings now Notably, will in also of Territory three we for in-person XXXX, are our and managers sales our think two XXXX. smaller, held
expect suggests $XX.X to sales quarter growth. XXX XX% record end organic with reps or XXXX for a we ahead, and XXX Looking QX guidance to million
also new our direct new countries. We’re QX, from opening sold office. we In Seoul products our first
worldwide. plan signed Korean XXth business $X.XX and international and previously our were up million in have and XX XXXX is direct distributor Our to of long-time market, we $XXX,XXX offices Korea XXXX. Korean about sales in net sales versus should our our now approximately be we buy Thailand XXXX. by a XXXX, term November largest to our Thai Korea distributor, in QX to Also we sheet distributors. two out office Bangkok a open
Turning MDA the see Europe, deadline to to MDR to were defer we legislation pass Brussels happy XXXX. until
filing the of with marks. MDR ahead pressing still our CE we’re However,
sales from MDR our nice quarter team, EMEA of applications, XX XXXX the before MDR our filed days CE our we’ll C January, we was the Pruitt problems. X FX CE XXXX. for shunts. XXXX/XXXX and the difficult a the received XX of first We final end recovery carotid a for mark Indeed, in have QX of now the somewhat file record
achievements. of Number the personnel XXX grew team XXX, of Dividend three, XXXX to over built and with call two, sales became $XXX. highlight member organically. LeMaitre Number X% J.J., Number like one, headcount the of we Index. we total several of manufacturing reps turning employees we Before Achievers sales I’d out several a to records,
factory to results including and and paying operations; MDRC undertook XenoSure the six, we invest Japan. applications, number and in off beyond. approvals, in XXXX and UK to initiatives continue with direct we Burlington. line regulatory RFA We in I APAC expansion Number in out build patches and albografts improved five, and to continue major China Germany these in a XXXX and forward look top warehouse bottom our
the will over call J.J. that, With turn to I